Carfilzomib (PR-171)

Catalog No.S2853

Carfilzomib (PR-171) Chemical Structure

Molecular Weight(MW): 719.91

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

Size Price Stock Quantity  
In DMSO USD 476 In stock
USD 170 In stock
USD 270 In stock
USD 670 In stock
USD 870 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Validation of activity and specificity of chemical inhibitors of; ATM, ATR, and DNAPK. H460 cells were treated with 1 uM camptothecin (CPT) or 20 ug/ml bleomycin for 1 h in the presence of the indicated inhibitors: DNAPK-i1—NU7026, DNAPK-i2—NU7441. MSH6,

    Sci Transl Med 2014 6(250), 250ra112. Carfilzomib (PR-171) purchased from Selleck.

    MM.1S cells were treated with or without carfilzomib (10 nM) in the presence or absence of TAS-117 (0.5 uM) for 24 h. Whole cell lysates were subjected to western blotting using CHOP, PARP, and GAPDH Abs.The graph represents fold changes of CHOP density relative to GAPDH.

    Cancer Res 2014 74(16), 4458-69. Carfilzomib (PR-171) purchased from Selleck.

  • Transduction at 24 h is indicated as normalized luciferase activity. HeLa cells were cotreated with 1 uM Carfilzomib and 500 vg/cell rAAV2-EGFP, and transduction was analyzed by flow cytometry at 24 h. Bright-field and EGPF fluorescence images at 24 h postransduction of cells visually indicating transduction.

    J Virol 2013 87(23), 13035-41. Carfilzomib (PR-171) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.
Targets
Proteasome [1]
(ANBL-6 cells)
5 nM
In vitro

Carfilzomib inhibits proliferation in a variety of cell lines and patient-derived neoplastic cells, including multiple myeloma, and induced intrinsic and extrinsic apoptotic signaling pathways and activation of c-Jun-N-terminal kinase (JNK). Carfilzomib reveals enhanced anti-MM activity compared with bortezomib, overcome resistance to bortezomib and other agents, and acts synergistically with dexamethasone (Dex). Carfilzomib shoes preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, with over 80% inhibition at doses of 10 nM. Short exposure to low-dose Carfilzomib leads to preferential binding specificity for the β5 constitutive 20S proteasome and the β5i immunoproteasome subunits. Measurement of caspase activity in ANBL-6 cells pulsed with Carfilzomib reveals substantial increases in caspase-8, caspase-9, and caspase-3 activity after 8 hours, giving a 3.2-, 3.9- and 6.9-fold increase, respectively, over control cells after 8 hours. In carfilzomib pulse-treated cells, the mitochondrial membrane integrity is decreased to 41% (Q1 + Q2), compared with 75% in vehicle-treated control cells. [1] In another study, Carfilzomib has also shown preclinical effectiveness against hematological and solid malignancies. [2] Carfilzomib directly inhibits osteoclasts formation and bone resorption. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MM.1S Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPC[2YxNTFyMDDuUS=> M2K1VlQ5KGh? NW\1RZBRUUN3MNMgQeKhOTBibl2= MlGwNlU{OTJ3NEO=
NCI-H929  MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjne2gxNTFyMDDuUS=> NV;0PHpGPDhiaB?= NUfNN|lZUUN3MDC9xsAyPCCwTR?= MXKyOVMyOjV2Mx?=
SUDHL16  M4TvVGFxd3C2b4Ppd{BCe3O|YYm= M17UOlIvPeLCk{OuOUBvVQ>? NYnCTHBsPDhiaB?= MYDlcohidmOnczD0bIUh[2WubDDk[YF1cCClbz30doVifG2nboSge4l1cCCDQ2mxNlE2 Mn\ZNlUzOzl7M{W=
SUDHL14 NVXDTGwySXCxcITvd4l{KEG|c4PhfS=> MXWyMlXjiJN|LkWgcm0> NE\LOpk1QCCq MVTlcohidmOnczD0bIUh[2WubDDk[YF1cCClbz30doVifG2nboSge4l1cCCDQ2mxNlE2 MWGyOVI{QTl|NR?=
U2932 NUfkc|l2SXCxcITvd4l{KEG|c4PhfS=> MWqyMlXjiJN|LkWgcm0> NG\CNnc1QCCq MXXlcohidmOnczD0bIUh[2WubDDk[YF1cCClbz30doVifG2nboSge4l1cCCDQ2mxNlE2 MW[yOVI{QTl|NR?=
P-UMSCC-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPT[HpKSzVyPUGxMlIhdk1? NGLiOpEzPDlzNUCzPS=>
R-UMSCC-1 NED0RphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HuRmlEPTB;MkK5OEBvVQ>? NXfyS|RPOjR7MUWwN|k>
P-Cal33 M1G2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLHTWM2OD1zNz6zJI5O MXeyOFkyPTB|OR?=
R-Cal33 M2TYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfOdpdSUUN3ME2xNVEzKG6P NIDteFgzPDlzNUCzPS=>
Jurkat NF3TTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:xMVEydk1? NWfrfZZiPDhiaB?= M2nadIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSvZX70JJdqfGhidn;ybY5we3SjdB?= NIra[WwzPDhyMUGyPC=>
Jurkat MV3BdI9xfG:|aYOgRZN{e2G7 NH;JOnU5KG6P NYm5[3VXOjRxNEigbC=> M{TpUIlv\HWlZYOgZZBweHSxc3nzMEBk[XOyYYPlJIFkfGm4YYTpc44tKGGwZDDQRXJRKGOuZXH2ZYdmKGOxLYTy[YF1dWWwdDD3bZRpKH[xcnnuc5N1[XR? NXrvZo04OjR6MEGxNlg>
UMSCC-22A M{H6OWFxd3C2b4Ppd{BCe3O|YYm= NVnrRpdQOjByIH7N M2rQXFI1KGh? MkDwbY5lfWOnIITo[UBk\WyuIHHwc5B1d3OrczDjc{11emWjdH3lcpQhf2m2aDDPUnghODlzMh?= MoizNlI6Ojl6MEO=
UMSCC-22B MVXBdI9xfG:|aYOgRZN{e2G7 MnrlNlAxKG6P NFXFXIYzPCCq MnnWbY5lfWOnIITo[UBk\WyuIHHwc5B1d3OrczDjc{11emWjdH3lcpQhf2m2aDDPUnghODlzMh?= NETGcFkzOjl{OUiwNy=>
1483 M{H1VWFxd3C2b4Ppd{BCe3O|YYm= NHfxZWgzODBibl2= NXLiR2U4OjRiaB?= NFSzS2pqdmS3Y3WgeIhmKGOnbHygZZBweHSxc3nzJINwNXS{ZXH0cYVvfCC5aYToJG9PYCByOUGy MUWyNlkzQThyMx?=
UMSCC-1 M4r6b2Fxd3C2b4Ppd{BCe3O|YYm= Mo\DNlAxKG6P NXP4d4cyOjRiaB?= NYLFc2lXcW6mdXPlJJRp\SClZXzsJIFxd3C2b4Ppd{Bkdy22cnXheI1mdnRid3n0bEBQVlhiMEmxNi=> NFzCPWkzOjl{OUiwNy=>
UMSCC-22A NWLPSlNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTN6LkegxtEhOS5yIH7N NWP2d5BGOjJ7Mkm4NFM>
UMSCC-22B NUfkSo81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rKNmlEPTB;M{CuO{DDuSB7LkOgcm0> M{XNTFIzQTJ7OECz
1483 M1zmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDzTWM2OD13MD61JOKyKDFzLkmgcm0> MnfDNlI6Ojl6MEO=
UMSCC-1 NGnB[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInlT2FKSzVyPUO0MlYhyrFiMj62JI5O NVPZTZVMOjJ7Mkm4NFM>
Cal33 NITaS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTR7LkOgxtEhQC57IH7N NWPCfWk1OjJ7Mkm4NFM>
PCI-15A MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;QOplWUUN3ME23NE41KMLzIEKyMlYhdk1? Mm\JNlI6Ojl6MEO=
PCI-15B MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmOzTWM2OD1|OT61JOKyKDFzLkCgcm0> NG\3cXYzOjl{OUiwNy=>
OSC-19 MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLkTWM2OD1zOD6zJOKyKDRwMjDuUS=> MVSyNlkzQThyMx?=
SUDHL16 MXvBdI9xfG:|aYOgRZN{e2G7 NYrHXFNDOi5yLUSuNEBvVQ>? NGLTSW41QCCq M2PjcYlv\HWlZYOgZ4VtdCCmZXH0bEBkdy22cnXheI1mdnRid3n0bEBw[mG2b3PsZZg> NVO5PYVlOjJ2MUG4PVk>
SUDHL16 MkjySpVv[3Srb36gRZN{[Xl? M4rwN|IvPSCwTR?= MWeyOEBp MnXPZYN1cX[jdHXzJGpPUyxiaX7hZ5RqfmG2ZYOgRWtVNCC3cD3y[Yd2dGG2ZYOgUo95[SxiYX7kJIlv\HWlZYOg{tNJOkFwWDDjc{11emWjdH3lcpQhf2m2aDDvZoF1d2OuYYi= M1T6dFIzPDFzOEm5
Granta NGjsPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yyc|AuPCCwTR?= MojuOFghcA>? MnzJbY5lfWOnIHPlcIwh\GWjdHigZ48ufHKnYYTt[Y51KHerdHigTGFFS0m| MoHoNlE4PTB{MkS=
SUDHL16 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWxMVQhdk1? NUHwOIFuOzZiaB?= MorwbY5lfWOnIHPlcIwh\GWjdHigZ48ufHKnYYTt[Y51KHerdHigTGFFS0m| MmP6NlAzOzN7N{O=

... Click to View More Cell Line Experimental Data

In vivo Carfilzomib moderately reduces tumor growth in an in vivo xenograft model. Carfilzomib effectively decreases multiple myeloma cell viability following continual or transient treatment mimicking. Carfilzomib increases trabecular bone volume, decreases bone resorption and enhances bone formation in non-tumor bearing mice. [3]

Protocol

Kinase Assay:[1]
+ Expand

Enzyme-linked immunosorbent assay for subunit profiling of carfilzomib:

ANBL-6 cells (2 × 106/well) are plated in 96-well plates and treated with Carfilzomib doses from 0.001 to 10 μM for 1 hour. Cells are then lysed (20 mM Tris-HCl, 0.5 mM EDTA), and cleared lysates are transferred to polymerase chain reaction (PCR) plates. A standard curve is generated using untreated ANBL-6 cell lysates starting at a concentration of 6 μg protein/μL. The active site probe [biotin-(CH2)4-Leu-Leu-Leu-epoxyketone; 20 μM] is added and incubated at room temperature for 1 hour. Cell lysates are then denatured by adding 1% sodium dodecyl sulfate (SDS) and heating to 100°C, followed by mixing with 20 μL per well streptavidin-sepharose high-performance beads in a 96-well multiscreen DV plate and incubated for 1 hour. These beads are then washed with enzyme-linked immunosorbent assay (ELISA) buffer (PBS, 1% bovine serum albumin, and 0.1% Tween-20), and incubated overnight at 4°C on a plate shaker with antibodies to proteasome subunits. Antibodies used included mouse monoclonal anti-β1, anti-β2, anti-β1i, and anti-β5i, goat polyclonal anti-β2i, and rabbit polyclonal anti-β5 (affinity-purified antiserum against KLH-CWIRVSSDNVADLHDKYS peptide). The beads are washed and incubated for 2 hours with horseradish peroxidase-conjugated secondary goat antirabbit, goat antimouse or rabbit antigoat antibodies. After washing, the beads are developed using the supersignal ELISA picochemiluminescence substrate. Luminescent detection is performed. Raw luminescence is converted to μg/mL by comparison with the standard curve and expressed as the % inhibition relative to vehicle control. Curve fits are generated using the following nonsigmoidal dose-response equation: Y = Bottom + (Top-Bottom)/(1 + 10̂((LogEC50 − X) × HillSlope)), where X is the logarithm of concentration, Y is the % inhibition, and EC50 is the dose showing 50% effect.
Cell Research:[1]
+ Expand
  • Cell lines: WST-1, ANBL-6 cells
  • Concentrations: 100 nM
  • Incubation Time: 1 hour
  • Method: WST-1 is used to determine the effects of proteasome inhibitor Carfilzomib on cell proliferation. The inhibition of proliferation is calculated in relation to parallel control cells that receives vehicle alone. A linear spline function is used to interpolate the median inhibitory concentration (IC50) using XLfit 4 software. The degree of resistance (DOR) is calculated using the formula: DOR = IC50(resistant cells)/IC50(sensitive cells). ANBL-6 cells pulsed with 100 nM carfilzomib are washed and suspended in PBS containing 5 μg/mL of JC-1, which exhibits potential-dependent accumulation in mitochondria. Analysis of the mitochondrial membrane potential-dependent color shift from 525 to 590 nm is carried out on a FacScan, and the data are analyzed with CellQuest software.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Beige-nude-XID mice
  • Formulation: 10% sulfobutylether β-cyclodextrin in 10 mmol/L citrate buffer pH 3.5,
  • Dosages: 2.0 mg/kg
  • Administration: i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 50 mg/mL (69.45 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+castor oil 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 719.91
Formula

C40H57N5O7

CAS No. 868540-17-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02802163 Not yet recruiting Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen April 30, 2017 Phase 1|Phase 2
NCT01402284 Active, not recruiting Multiple Myeloma National Cancer Institute (NCI)|Celgene|Onyx Therapeutics, Inc.|National Institutes of Health Clinical Center (CC) July 21, 2011 Phase 2
NCT03031730 Not yet recruiting Hypercalcemia|Plasmacytoma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma National Cancer Institute (NCI) October 2017 Phase 1
NCT03029234 Not yet recruiting Relapsed and Refractory Multiple Myeloma Amgen|Onyx Therapeutics, Inc. February 2017 Phase 3
NCT02891811 Not yet recruiting Multiple Myeloma Arbeitsgemeinschaft medikamentoese Tumortherapie|Amgen January 2017 Phase 2
NCT03004287 Not yet recruiting Multiple Myeloma University of Arkansas|Janssen, LP January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Carfilzomib (PR-171) | Carfilzomib (PR-171) supplier | purchase Carfilzomib (PR-171) | Carfilzomib (PR-171) cost | Carfilzomib (PR-171) manufacturer | order Carfilzomib (PR-171) | Carfilzomib (PR-171) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID